Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | PRNP | P04156 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15359030 | 0.87 | GRM1 (0.39) | GRM1BACE1KCNH2NR1I2HTR1A | |
| SCHEMBL13166990 | 0.87 | GRM1 (0.41) | GRM1BACE1L3MBTL1CYP1A2CYP2D6 | |
| SCHEMBL23175554 | 0.86 | ALDH1A1 (0.40) | GRM1BACE1KCNH2RXFP1NR1I2 | |
| SCHEMBL31125772 | 0.86 | BACE1 (0.41) | GRM1BACE1KCNH2NR1I2HTR1A | |
| SCHEMBL23151892 | 0.83 | GRM1 (0.42) | GRM1KCNH2L3MBTL1RXFP1CACNA1C | |
| SCHEMBL296886 | 0.81 | KCNH2 (0.42) | KCNH2NR1I2HTR1AHTR2ASLC6A3 | |
| SCHEMBL20776919 | 0.81 | KCNH2 (0.46) | GRM1KCNH2NR1I2HTR1AHTR2A | |
| SCHEMBL6523099 | 0.80 | KCNH2 (0.39) | GRM1BACE1KCNH2NR1I2HTR1A | |
| SCHEMBL19330207 | 0.80 | KCNH2 (0.43) | GRM1KCNH2L3MBTL1NR1I2HTR1A | |
| SCHEMBL12277874 | 0.80 | KCNH2 (0.37) | GRM1PSMB5KCNH2L3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687277-B1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-04 | — | — | EP | disclosed |
| EP-1694653-B1 | 6-(HETERO-)CYCLOHEXYLALKYL SUBSTITUTED 2-QUINOLINONES/2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-20 | — | — | EP | disclosed |
| US-9115084-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2015-08-25 | — | — | US | disclosed |
| EP-1709012-B1 | 6-SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-29 | — | — | EP | disclosed |
| US-8802671-B2 | Quinoline derivatives as antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-12 | — | — | US | disclosed |
| US-8802671-B2 | Quinoline derivatives as antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-12 | — | — | US | disclosed |
| US-20130237528-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-12 | — | — | US | disclosed |
| CN-102206180-B | Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA NV | 2013-05-29 | — | — | CN | disclosed |
| US-8450486-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-28 | — | — | US | disclosed |
| EP-1912648-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-10 | — | — | EP | disclosed |
| US-20070072842-A1 | 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors | JANSSEN-CILAG (FR) | 2007-03-29 | — | — | US | disclosed |
| WO-2007014941-A2 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-08 | — | — | WO | disclosed |
| CN-1890225-A | Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly (ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-03 | — | — | CN | disclosed |
| EP-1709012-A1 | 6-SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-11 | — | — | EP | disclosed |
| EP-1694653-A1 | SUBSTITUTED 6-CYCLOHEXYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-30 | — | — | EP | disclosed |
| EP-1687277-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005058843-A1 | SUBSTITUTED 6-CYCLOHEXYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005054201-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005054210-A1 | 6-SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-16 | — | — | WO | disclosed |
| WO-2003082350-A2 | RADIOLABELLED QUINOLINE AND QUINOLINONE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072842-A1 | 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors | PARP1, PARP6, PARP2 | GRM1 3930/4885PSMB5 1685/4885BACE1 2506/4885 |
| US-20130237528-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | PARP1, PARP2, PARP6 | GRM1 4270/4885PSMB5 3084/4885BACE1 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.